为了使您在Abcam官网的浏览体验更顺畅，请使用最新版本的浏览器比如 Google Chrome
In Vitro Angiogenesis Assay kit (ab204726) provides a quick and robust method to measure the ability of endothelial cells to from three-dimensional tube-like structures in vitro in less than 18 hours. This product provides a simple, easy to perform, qualitative tool for assessing angiogenesis.
In vitro cell-based assays using calf pulmonary aortic endothelial (CPAE), human umbilical vein endothelial cells (HUVEC), or other endothelial cells grown on an extracellular matrix containing collagen are important tools for identifying factors that regulate angiogenesis. A number of such in vitro assays have been developed in the past, but these assays have been somewhat limited in their application due to the short duration which the cultured cells live, and the complexity of the assays.
Angiogenesis is a physiological process that occurs during wound healing and normal development which involves the growth of new blood vessels from pre-existing vessels. These blood vessels form highly branched, tree-like tubular networks that ensure efficient and simultaneous transport of gases, liquids, nutrients, signaling molecules, and circulating cells between tissues and organs. Angiogenesis is complex and highly regulated, with tight coordination of cell proliferation, differentiation, migration, matrix adhesion, and cell-to-cell signaling. Angiogenesis is regulated by several factors, most importantly growth factors such as vascular endothelial growth factors (VEGFs) and platelet-derived growth factors (PDGFs).
While normal angiogenesis is critical for homeostasis, abnormal angiogenesis is a significant component of several diseases, most notably cancer. Angiogenesis is essential for tumor development and metastasis. Inhibition of angiogenesis is one of the main therapeutic targets in cancer drug discovery. Angiogenesis inhibitors such as Tarceva have been widely used in the United States and other countries to treat lung cancer. Most of these inhibitors target elements of growth factor-receptor signaling pathways. JNJ-10198409 is one of these molecules that inhibits the tyrosine kinase activity of the PDGF receptor.
|Extracellular Matrix Solution||2 x 1.25ml|
|Inhibitor Control -Vinblastine||1 x 10µl|
|Staining Dye Concentrate||1 x 25µl|
|Wash Buffer||1 x 10ml|
Our Abpromise guarantee covers the use of ab204726 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||Use at an assay dependent concentration.|
HUVEC morphogenesis on Extracellular Matrix Gel. Cells (2 × 104) were plated per 1 cm2 well precoated with Extracellular Matrix Gel and grown for 18 hours (A) in the specific medium alone (positive control) or containing (B) PMA 10 µmol/L.
Phase contrast (a, c, e) and fluorescent images (b, d, f) of endothelial cells in a tissue culture plate. (a, b) Before treatment, (c, d) Tube formation of endothelial cells on Extracellular Matrix Gel. (e, f) endothelial cells on Extracellular Matrix Gel treated with Vinblastine (1 pmol/L).
ab204726 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"